4Moving Biotech’s 4P004 GLP-1 analog gains FDA Fast Track status for knee osteoarthritis

4Moving Biotech, a clinical-stage biotechnology company headquartered at the Pasteur Institute in Lille, France, announced receipt of US FDA Fast Track Designation for 4P004, a glucagon-like peptide-1 (GLP-1) analog engineered for intra-articular administration. The award focused on the molecule’s potential use as a third-line treatment of knee osteoarthritis in patients with synovitis.

Fast Track Designation enables more frequent FDA interactions during development, including rolling review of data, and applies here to a program that has no prior expedited designation on record. The designation is specifically scoped to a treatment-refractory knee osteoarthritis subpopulation defined by the presence of synovitis, a narrower target than the broader disease category.

4P004 is formulated for direct injection into the knee joint rather than systemic administration. The company describes it as leveraging GLP-1’s analgesic, anti-inflammatory, anti-catabolic, and anabolic properties across joint tissues, with the intent of modifying disease progression rather than providing symptomatic relief alone. 4Moving Biotech was spun out of 4P-Pharma in mid-2020 and does not carry a stock exchange listing.

The Phase I LASARE trial, results from which were disclosed in June 2024, enrolled 34 patients with knee osteoarthritis across three Belgian sites in a randomized, double-blind, placebo-controlled design. Single intra-articular injections of 4P004 were tested at doses from 0.3 mg to 3.0 mg. The trial met its primary safety objective, with expected adverse events in the 4P004 groups comparable to placebo. Pharmacokinetic data showed systemic liraglutide exposure below levels reported for subcutaneous administration of the approved formulation Victoza, which the company cited as supporting a 505(b)(2) regulatory pathway in the US. A pharmacologically active dose was identified from the ascending-dose cohorts. No specific pain endpoint scores, p-values, or quantitative PK parameters were disclosed in the public announcement; those figures were not available in any parallel public source at the time of writing.

The ongoing Phase IIa INFLAM MOTION trial (CTIS2024-518916-38-00) is a multicenter, randomized, double-blind, placebo-controlled proof-of-concept study enrolling patients with knee synovitis and osteoarthritis across sites in the EU and North America. Topline results are expected in early 2027. The company states that US enrollment was enabled following an Investigational New Drug (IND) clearance in January 2025.

Research context

No disease-modifying osteoarthritis drug (DMOAD) has received regulatory approval from the US FDA, EMA, or any other major agency. Approved pharmacological options for knee osteoarthritis — including non-steroidal anti-inflammatory drugs, duloxetine, and intra-articular corticosteroids or hyaluronic acid — address symptoms without altering structural disease progression. The subpopulation targeted by 4P004, patients with active synovitis who have failed multiple prior therapies, has no approved disease-modifying option.

4P004’s mechanistic distinction from prior DMOAD candidates lies in its use of the GLP-1 pathway at the joint level. Unlike sprifermin, which targets chondrocyte proliferation via FGF18, or lorecivivint, which inhibits CLK2 and DYRK1A to modulate Wnt signaling, 4P004 is positioned to act on inflammatory, catabolic, and anabolic pathways simultaneously through GLP-1 receptor engagement in joint tissue. The intra-articular route is shared with sprifermin and lorecivivint, and is intended to limit systemic exposure — a design rationale that the LASARE PK data were cited to support.

The GLP-1 receptor biology underlying 4P004 is distinct from the systemic metabolic applications of GLP-1 agonists such as semaglutide or liraglutide. Whether GLP-1 receptor expression in synovial tissue and chondrocytes is sufficient to drive the anti-catabolic and anabolic effects the company describes has not been established in peer-reviewed clinical data from the 4P004 program to date. The INFLAM MOTION trial is designed to generate the translational evidence needed to address that question.